Skip to main content

Table 1 The demographic data of the enrolled participants

From: The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study

  Participants without priming (n = 71) Participants primed with A/Indonesia/05/2005 (n = 34) Participants primed with A/Vietnam/1194/2004 and A/Indonesia/05/2005 (n = 26)
Age group (years) (%)    
20-29 33 (46)a 21 (62) 10 (38)
30-44 27 (38) 10 (29) 13 (50)
45-60 11 (15) 3 (9) 3 (12)
Gender, Female (%) 51 (72) 8 (24) 2 (8)
  1. aBecause the percentage in each age group was rounded off, the sum of the numbers in the column was added up to 99% only.